Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder

Dong-Hwan Yun, Chi-Un Pae, Antonio Drago, Laura Mandelli, Diana De Ronchi, Ashwin A Patkar, In Ho Paik, Alessandro Serretti, Jung-Jin Kim

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

4 Citationer (Scopus)

Abstract

OBJECTIVE: We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment.

METHODS: A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (+/-19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T, rs2005976 G/A, rs760761 C/T and rs2619522 A/C).

RESULTS: There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors.

CONCLUSION: Although the small number of subjects is an important limitation in our study, DTNBP1 does not seem to be involved in acute antimanic efficacy.

OriginalsprogEngelsk
TidsskriftPsychiatry investigation
Vol/bind5
Udgave nummer2
Sider (fra-til)102-5
Antal sider4
ISSN1738-3684
DOI
StatusUdgivet - jun. 2008
Udgivet eksterntJa

Fingeraftryk

Dyk ned i forskningsemnerne om 'Effect of the dysbindin gene on antimanic agents in patients with bipolar I disorder'. Sammen danner de et unikt fingeraftryk.

Citationsformater